Wharton's Jelly derived Mesenchymal stem cell therapy (BioXcellerator)

N/A

Report date: 2024/08/28 20:00:53

Base Information

Drug NameWharton's Jelly derived Mesenchymal stem cell therapy (BioXcellerator)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Source of cells > Wharton's Jelly-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionImmunomodulatorsStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsRespiratory Distress Syndrome, Adult

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryColombia

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBioXcellerator SAS

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBioXcellerator SAS

Active IndicationsN/A

Inactive IndicationsRespiratory Distress Syndrome, Adult

Other Information

ATC CodeN/A